Clinical Trials in Germany — Country Dashboard | 3,925 EU Studies

Filter these 3,925 trials by condition, phase, sponsor and more.

Open in Search →

3,925 Registered trials

1,469 Recruiting

2,141 Completed trials

967 Sponsors active

2,431 Research sites

Phase III

Phase II

Phase III: 1706 Phase II/III: 163 Phase II: 1037 Phase I/II: 215 Phase III/IV: 28 Phase IV: 138 Phase I: 198 Phase I (Other): 297 Phase I (FiH): 120 Other: 22 Other: 1

Oversight events in trials active here:

118 serious breaches 847 temporary halts 65 urgent safety measures 91 unexpected events 153 corrective measures across 499 trials

View oversight register →

Top conditions

Non-small cell lung cancer 112 Systemic lupus erythematosus 38 Non-small cell lung cancer metastatic 38 Breast cancer 28 Ovarian cancer 28 Colorectal cancer 28 Rheumatoid arthritis 27 Asthma 26 Obesity 25 Crohn's disease 24 Pulmonary arterial hypertension 23 Colitis ulcerative 23

Top sponsors

Novartis Pharma AG 166 AstraZeneca AB 165 Merck Sharp & Dohme LLC 146 Boehringer Ingelheim International GmbH 128 F. Hoffmann-La Roche AG 125 Janssen - Cilag International 113 AbbVie Deutschland GmbH & Co. KG 89 Sanofi-Aventis Recherche & Developpement 80 Novo Nordisk A/S 67 Pfizer Inc. 67 Eli Lilly & Co. 59 Amgen Inc. 58

Cities with most trials

All 570 cities →

All trials — page 140

3,925 total

Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (Neo… Ended

2024-515660-31-00 Phase II intrahepatic cholangiocarcinoma Universitaetsklinikum Schleswig-Holstein AöR
A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants with Nonsegmental Vitiligo Ended

2022-501668-16-00 Phase III NON SEGMENTAL VITILIGO Pfizer Inc.
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended

2024-512554-15-00 Phase III COVID-19 AstraZeneca AB
A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease Ended

2024-515177-94-00 Phase II Parkinson's Disease Cavion Inc.
A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly… Ended

2022-500275-31-00 Phase III Haemophilia A Swedish Orphan Biovitrum AB (publ)
ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney … Ended

2022-501802-36-00 Phase III Prevention of cardiac surgery associated acute kidney injury Alexion Pharmaceuticals Inc.
Evaluation of the Effects of Neurexan® on Short-Term Insomnia, Daytime Performance and Stress Response by Polysomnography (PSG), Electroence… Ended

2024-514391-41-00 Phase II Short-Term Insomnia Biologische Heilmittel Heel GmbH
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Phase III Hidradenitis Suppurativa Incyte Corp.
Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones. Ended

2024-512647-23-00 Phase II Grave's disease Immunovant Sciences GmbH
ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended

2022-500535-36-01 Phase III Moderately to severely active ulcerative colitis Abivax
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Phase III Moderately to severely active ulcerative colitis Abivax
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended

2022-500101-41-00 Phase IV Type 2 Diabetes Eli Lilly Cork Limited
A study to test whether spesolimab helps people with skin disease called Netherton syndrome Ended

2022-501104-10-00 Phase II/III Netherton syndrome (NS) Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
Efficacy, Safety, Tolerability Study of LYR-210 Depot in Chronic Sinusitis Ended

2023-506268-15-00 Phase III Chronic Rhinosinusitis (CRS) in Adults Lyra Therapeutics Inc.
Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Ended

2024-512649-18-00 Phase III Thyroid Eye Disease Immunovant Sciences GmbH
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended

2022-500177-13-00 Phase II Metastatic Colorectal Cancer (mCRC) Gilead Sciences Inc.
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501753-36-00 Phase III Hidradenitis Suppurativa Incyte Corp.
A randomized, double-blind, single-center, 2-period cross-over Phase I study to assess the tolerability, safety and pharmacokinetics of anti… Ended

2023-503971-45-00 Phase I (Other) Depression Ketabon GmbH
Efficacy and tolerability of horse chestnut seed extract on swelling in patients undergoing meniscus surgery: a placebo-controlled, randomiz… Ended

2022-501154-11-00 Phase II post-operative swelling, pain and edema Cesra Arzneimittel GmbH & Co. KG
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Phase III/IV Dermatitis atopic AbbVie Deutschland GmbH & Co. KG
A study to investigate improvement in physical function in SF-36 with Vericiguat compared with Placebo in participants with post-COVID-19 sy… Ended

2024-517713-33-00 Phase II Post-COVID-19 syndrome without (PCS) or with (PCS/CFS) fulfi… Charite Universitaetsmedizin Berlin KöR
A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC. Ended

2022-501047-32-00 Phase I (Other) ULCERATIVE COLITIS Pfizer Inc.
A study to learn how safe the study treatment BAY3401016 is, how it affects the body and how it moves into, through, and out of the body whe… Ended

2022-502319-12-00 Phase I Alport syndrome Bayer AG
Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended

2023-509471-17-00 Phase II Metastatic or unresectable locally advanced BRAF V600E/K mut… Pfizer Inc.

Showing 3,337–3,360 of 3,925 trials

← All countries